Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders
Open Access
- 1 November 2018
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 5 (6) , e498
Abstract
Objective To evaluate the long-term effects of rituximab (RTX) on total and specific immunoglobulins (Igs) in patients with neuromyelitis optica spectrum disorders (NMOSDs). Methods Total IgG, IgA, and IgM levels were evaluated in 15 patients with NMOSDs treated with RTX (median follow-up 70 months). Anti-aquaporin 4 (AQP4)-IgG titration was performed on samples from 9 positive patients. Anti-tetanus (TET), anti-varicella-zoster virus (VZV), and anti-Epstein–Barr virus nuclear antigen (EBNA) IgGs were also tested in patients with NMOSDs and in 6 healthy controls (HCs). Results RTX reduced total IgG by 0.42 g/L per year, IgA by 0.08 g/L per year, and IgM by 0.07 g/L per year. Hypogammaglobulinemia (hypo-IgG) (IgG < 7 g/L) developed in 11/15 patients. Severe hypo-IgG (IgG < 4 g/L) was found in 3/15 patients, of whom 2 patients developed serious infectious complications. In group analysis, anti-AQP4 IgG titers were reduced by RTX over time, and a significant correlation between anti-AQP4 IgG titers and total IgG levels was found. The effects of RTX were observed on pathogen-specific IgGs as well. In particular, the levels of anti-TET IgG in patients were significantly lower than those in HCs. The half-life of anti-TET IgG was reduced by about 50% in patients compared with the general population. Conclusions Long-term RTX treatment is associated with the risk of hypo-Ig and reduction of anti-TET protection in patients with NMOSDs. Results obtained in this study suggest the importance of monitoring total and specific Ig levels before and during treatment with anti-CD20 drugs to prevent hypo-Ig–related complications and to optimize clinical management.Keywords
This publication has 41 references indexed in Scilit:
- Distinct features between longitudinally extensive transverse myelitis presenting with and without anti-Aquaporin 4 antibodiesMultiple Sclerosis Journal, 2012
- Evaluation of a Multiparametric Immunofluorescence Assay for Standardization of Neuromyelitis Optica SerologyPLOS ONE, 2012
- Perceptions and Experiences of Research Participants on Gender-Based Violence Community Based Survey: Implications for Ethical GuidelinesPLOS ONE, 2012
- Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patientsJournal of Neuroinflammation, 2012
- Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4Multiple Sclerosis Journal, 2011
- Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapyJournal of Gastroenterology, 2010
- Duration of Humoral Immunity to Common Viral and Vaccine AntigensNew England Journal of Medicine, 2007
- Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeksArthritis & Rheumatism, 2006
- Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2004
- Maintenance of Serological Memory by Polyclonal Activation of Human Memory B CellsScience, 2002